Zobrazeno 1 - 10
of 348
pro vyhledávání: '"Lipid-lowering drug"'
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract To determine the potential causal association between serum lipid levels and sarcoidosis, and to investigate the potential impact of lipid lowering agents on sarcoidosis. Two-sample Mendelian randomization (TSMR) was used to investigate the
Externí odkaz:
https://doaj.org/article/85a07ef2551142079ec706bb76d77bbd
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
IntroductionThe primary objective of this systematic review was to provide an overview of the efficacy and safety of various lipid-lowering therapies in patients post-kidney transplant (PKT), given the limited existing literature. Considering the res
Externí odkaz:
https://doaj.org/article/ceeeb304656f4b7891ad9e5a90a6aa12
Publikováno v:
All Life, Vol 17, Iss 1 (2024)
OBJECTIVES This genetics-based study aimed to evaluate the relationships of long-term lipid-lowering agents on lung-related diseases (LRD) outcomes. METHODS We extracted genetic variations of six drug target genes from a major genome-wide association
Externí odkaz:
https://doaj.org/article/b48cc6145f3b43e3b2f599d1b17a66c6
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 16, Iss 1, Pp 1-8 (2024)
Abstract Background Inflammatory bowel disease (IBD) has been associated with lipid-lowering drugs in observational studies. Drug-target Mendelian randomization (MR) was utilized in this study to examine the causal relationship between lipid-lowering
Externí odkaz:
https://doaj.org/article/e24584de02384d41952f5c24f6ca72ea
Autor:
Liang Yang, Mingyuan Xu, Xixi Gao, Jingwen Liu, Dingkai Zhang, Zhaohua Zhang, Zhidong Ye, Jianyan Wen, Peng Liu
Publikováno v:
Reviews in Cardiovascular Medicine, Vol 25, Iss 8, p 292 (2024)
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9), 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), cholesteryl ester transfer protein (CETP) and apolipoprotein C3 (APOC3) are pivotal regulators of lipid metabolism, with licen
Externí odkaz:
https://doaj.org/article/d96ba0c7ba4043b78fd436db65a449de
Publikováno v:
Health Expectations, Vol 27, Iss 2, Pp n/a-n/a (2024)
Abstract Background The emergence of proprotein convertase subtilisin/kexin type 9 inhibitors offered dyslipidemia patients an alternative to statins for lipid‐lowering treatment. Understanding patient and physician preferences for lipid‐lowering
Externí odkaz:
https://doaj.org/article/4dbbde279dd44d4e94ed9848ab56ae81
Autor:
Honglin Li, Lei Zhang, Feiran Yang, Xiaoteng Feng, Rong Fu, Ruohan Zhao, Xiurong Li, Huijie Li
Publikováno v:
Frontiers in Genetics, Vol 14 (2023)
Background: The causal relationship between lipid-lowering drug (LLD) use and lung cancer risk is controversial, and the role of sphingolipid metabolism in this effect remains unclear.Methods: Genome-wide association study data on low-density lipopro
Externí odkaz:
https://doaj.org/article/22f29778d51c43cf8082499a054b6411
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Chunxia Shi, Zugui Zhang, Jordan Goldhammer, David Li, Bob Kiaii, Victor Rudriguez, Douglas Boyd, David Lubarsky, Richard Applegate, Hong Liu
Publikováno v:
BMC Anesthesiology, Vol 22, Iss 1, Pp 1-8 (2022)
Abstract Background Increased life expectancy and improved medical technology allow increasing numbers of elderly patients to undergo cardiac surgery. Elderly patients may be at greater risk of postoperative morbidity and mortality. Complications can
Externí odkaz:
https://doaj.org/article/8a6bbe6ed29e4d2298239a14ad4e6025